Adropin, Insulin, Insulin Resistance and Lipid Profile Levels in Diabetes Mellitus Type2 Patients

Abstract

Background: Type 2 diabetes mellitus (T2DM) is non-insulin-dependent diabetes or diabetes that affects adults, and it represents 90% of diabetics and it occurs as a result of insulin resistance and a defect in insulin production. We aimed to evaluate levels of adropin, insulin, insulin resistance and lipid profile levels in diabetes mellitus type2 patients. Aim: The current study aimed to investigate the relationship between type 2 diabetes mellitus and liver and adipose tissue by measuring the level of secreted Hepatokines and a number of hormonal and biochemical parameters in men. Materials and Methods: The study group include 60 men with type 2 diabetes mellitus and a control group of 30 healthy men. Proteins and biochemistry assays include Adropin levels, insulin, Fasting blood sugar, Insulin resistance indicators(HOMA-IR,HOMA-B,QUICKI),Total cholesterol, Triglycerides, High-density lipoprotein for cholesterol, Low-density lipoprotein for cholesterol, Very high-density lipoprotein for cholesterol, Phospholipid and Atherogenic index. Results: There was a significant increase at (P≥0.05) in Adropin levels, Fasting blood sugar, Total cholesterol, triglycerides, High-density lipoprotein for cholesterol, Low-density lipoprotein for cholesterol, Very high-density lipoprotein for cholesteroland Phospholipid in type 2 diabetes mellitus men compared to control group. while insulin and HOMA-B show significant decrease at (P≥0.05) in type 2 diabetes mellitus men compared to control group. Atherogenic index, HOMA-IR and QUICKI didn’t show any significant difference between both groups. Conclusions: We conclude from the results of the current study that there is a relationship between type 2 diabetes mellitus and liver dysfunctions through a secretion imbalance of Adropin that indicates an association between liver disease and type 2 diabetes mellitus. The metabolic imbalances or risks of insulin resistance can lead to hyperglycemia, dyslipidemia, and obesity.